In contrast, docking analyses with four key anti-tumor targets: VEGFR2 (PDB ID: 3VO3), MET (PDB ID: 3DKC), RET (PDB ID: 2IVU), and Trk-A (PDB ID: 6PL3) revealed only weak interactions, including Pi-Anion, Pi-Alkyl, and Pi-Cation interactions, rather than strong hydrogen bonding. The gene discussed is RET; the disease is neoplasm.